Comparison of the QUANTIPLEX HIV-1 RNA 2.0 Assay with the AMPLICOR HIV-1 MONITOR 1.0 Assay for Quantitation of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma of Patients Receiving Stavudine-Didanosine Combination Therapy
暂无分享,去创建一个
M. Peeters | C. Pasquier | J. Puel | J. Izopet | M. Segondy | J. Reynes | I. Pellegrin | B. Montes | B. Dumon | H. Fleury
[1] W. S. Clark,et al. Clinical Comparison of an Enhanced-Sensitivity Branched-DNA Assay and Reverse Transcription-PCR for Quantitation of Human Immunodeficiency Virus Type 1 RNA in Plasma , 1998, Journal of Clinical Microbiology.
[2] R. Sperling,et al. Absolute Copy Number and Relative Change in Determinations of Human Immunodeficiency Virus Type 1 RNA in Plasma: Effect of an External Standard on Kit Comparisons , 1998, Journal of Clinical Microbiology.
[3] S. Hammer,et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. , 1998, Journal of Infectious Diseases.
[4] S. Kwok,et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity , 1997, Journal of clinical microbiology.
[5] J Sninsky,et al. The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studies. , 1997, Nucleic acids research.
[6] M. Peeters,et al. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of medical virology.
[7] F. Brun-Vézinet,et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of clinical microbiology.
[8] M. Urdea,et al. An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of clinical microbiology.
[9] K. Harada,et al. Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.
[10] S. Hammer,et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.
[11] J. Kahn,et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.
[12] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[13] G. Zissis,et al. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of clinical microbiology.
[14] M. Clementi,et al. Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection , 1996, Clinical microbiology reviews.
[15] J. Sninsky,et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.
[16] D. van Strijp,et al. Quantification of HIV-1 RNA in plasma using NASBA during HIV-1 primary infection. , 1993, Journal of virological methods.
[17] J. Sninsky,et al. Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals , 1990, Journal of clinical microbiology.